Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications.
Excellent balance sheet with proven track record.
Share Price & News
How has Biotage's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PQX1's share price has been volatile over the past 3 months.
7 Day Return
DE Life Sciences
1 Year Return
DE Life Sciences
Return vs Industry: PQX1 underperformed the German Life Sciences industry which returned 53.1% over the past year.
Return vs Market: PQX1 exceeded the German Market which returned 3.9% over the past year.
Price Volatility Vs. Market
How volatile is Biotage's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biotage undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PQX1 (€14.54) is trading above our estimate of fair value (€5.25)
Significantly Below Fair Value: PQX1 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PQX1 is good value based on its PE Ratio (49.2x) compared to the XE Life Sciences industry average (65.6x).
PE vs Market: PQX1 is poor value based on its PE Ratio (49.2x) compared to the German market (21x).
Price to Earnings Growth Ratio
PEG Ratio: PQX1 is poor value based on its PEG Ratio (6.3x)
Price to Book Ratio
PB vs Industry: PQX1 is overvalued based on its PB Ratio (10.3x) compared to the XE Life Sciences industry average (6.1x).
How is Biotage forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PQX1's forecast earnings growth (7.8% per year) is above the savings rate (0.2%).
Earnings vs Market: PQX1's earnings (7.8% per year) are forecast to grow slower than the German market (22.4% per year).
High Growth Earnings: PQX1's earnings are forecast to grow, but not significantly.
Revenue vs Market: PQX1's revenue (10.9% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: PQX1's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PQX1's Return on Equity is forecast to be low in 3 years time (18.5%).
How has Biotage performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PQX1 has high quality earnings.
Growing Profit Margin: PQX1's current net profit margins (17.7%) are lower than last year (17.9%).
Past Earnings Growth Analysis
Earnings Trend: PQX1's earnings have grown significantly by 21.8% per year over the past 5 years.
Accelerating Growth: PQX1's earnings growth over the past year (17.8%) is below its 5-year average (21.8% per year).
Earnings vs Industry: PQX1 earnings growth over the past year (17.8%) exceeded the Life Sciences industry 8.4%.
Return on Equity
High ROE: PQX1's Return on Equity (20.9%) is considered high.
How is Biotage's financial position?
Financial Position Analysis
Short Term Liabilities: PQX1's short term assets (SEK655.1M) exceed its short term liabilities (SEK200.4M).
Long Term Liabilities: PQX1's short term assets (SEK655.1M) exceed its long term liabilities (SEK269.2M).
Debt to Equity History and Analysis
Debt Level: PQX1's debt to equity ratio (11.4%) is considered satisfactory.
Reducing Debt: PQX1's debt to equity ratio has increased from 1% to 11.4% over the past 5 years.
Debt Coverage: PQX1's debt is well covered by operating cash flow (237.4%).
Interest Coverage: PQX1 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Biotage current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PQX1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PQX1's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PQX1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PQX1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PQX1 is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PQX1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tomas Blomquist (50yo)
Mr. Tomas Blomquist has been CEO and President of Biotage AB since November 6, 2019. Mr. Blomquist served as the Chief Operating Officer of Analyticon Biotechnologies AG. Mr. Blomquist served as Vice Presi ...
CEO Compensation Analysis
Compensation vs Market: Tomas's total compensation ($USD419.66K) is below average for companies of similar size in the German market ($USD1.43M).
Compensation vs Earnings: Insufficient data to compare Tomas's compensation with company performance.
|CEO & President||0.67yr||kr3.85m||0.023% SEK218.8k|
|Chief Financial Officer||0.25yr||no data||no data|
|Executive Vice president of Operations||10.17yrs||no data||0.0048% SEK45.9k|
|Chief Scientific Officer||no data||no data||no data|
|Chief Legal Officer||no data||no data||0.031% SEK291.6k|
|Executive Vice President of Global Marketing||no data||no data||0.0029% SEK27.4k|
|Global Human Resources Director||no data||no data||0.00049% SEK4.7k|
|Chief Auditor||no data||no data||no data|
|President of Biosystems||no data||no data||no data|
|Vice President and Chief Executive Officer of North America||no data||no data||no data|
Experienced Management: PQX1's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.
|Employee Representative Director||no data||no data||0.00077% SEK7.3k|
|Employee Representative Director||1.83yrs||no data||no data|
|Deputy Employee Representative Director||0.67yr||no data||no data|
|Deputy Employee Representative Director||0.67yr||no data||no data|
Experienced Board: PQX1's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PQX1 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biotage AB's company bio, employee growth, exchange listings and data sources
- Name: Biotage AB
- Ticker: PQX1
- Exchange: DB
- Founded: 1969
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr9.878b
- Listing Market Cap: kr950.852m
- Shares outstanding: 65.20m
- Website: https://www.biotage.com
Number of Employees
- Biotage AB
- Box 8
- Uppsala County
- 751 03
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BITG.F||OTCPK (Pink Sheets LLC)||Yes||Series A Common Stock||US||USD||Jun 2000|
|BIOT||OM (OMX Nordic Exchange Stockholm)||Yes||Series A Common Stock||SE||SEK||Jun 2000|
|0GRP||LSE (London Stock Exchange)||Yes||Series A Common Stock||GB||SEK||Jun 2000|
|PQX1||DB (Deutsche Boerse AG)||Yes||Series A Common Stock||DE||EUR||Jun 2000|
|BIOTS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Series A Common Stock||GB||SEK||Jun 2000|
|PQX||XTRA (XETRA Trading Platform)||SEK1 SER'A'||DE||EUR||Feb 2007|
Biotage AB (publ), a life science company, provides separation technologies in the areas of organic and analytical chemistry, biomolecules, as well as for industrial scale up applications. It offers sample preparation solutions; horizon food and environmental products; microwave synthesis solutions; peptide synthesis and purification solutions; flash purification products; work-up products; evaporation and concentration solutions; and industrial and large scale products, such as flash purification, metal scavenging, reagents and scavengers, and custom resins. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government authorities, and academic institutions; and commercial labs, hospital, CROs, bio-analytical laboratories, food manufacturers, and labs performing for food safety and environmental analysis. It operates in North and South America, Europe, Japan, China, South Korea, India, the Middle East, Africa, and Asia Pacific. The company was founded in 1969 and is headquartered in Uppsala, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/11 21:35|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.